Entheon Biomedical Corp.

As of May 31, 2026, Entheon Biomedical Corp. has 13.86M shares outstanding.

As of May 31, 2026, Entheon Biomedical Corp. maintains a current ratio of 12.16, meaning it holds 12.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended May 31, 2026, Entheon Biomedical Corp. posted a return on equity (ROE) of 4.90, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.59 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.42, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.90, useful for judging operating efficiency across full business cycles. The company generates approximately - - in revenue per employee across its workforce of 24.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Entheon Biomedical Corp.'s stock has declined approximately 23.60% over the past 52 weeks. The 50-day moving average sits at 0.04, while the 200-day moving average is 0.05.

Over the twelve months ended May 31, 2026, Entheon Biomedical Corp. generated - - in revenue and converted that into 14,909.66 in net income, yielding earnings per share of 0.00. EBITDA reached 7,877.11, while operating income came in at -209,791.27.

These figures are as of May 31, 2026. Total book value stands at 298,210.66, with working capital of 295,101.11 providing operational flexibility.

Entheon Biomedical Corp. produced -108,013.89 in operating cash flow over the twelve months ended May 31, 2026.

Entheon Biomedical Corp.'s most recent stock split took place on March 1, 2024 with a 10:1 split ratio.